When to update COVID-19 vaccine composition DOI Open Access
Rebecca Grant, Jilian A. Sacks, Priya Abraham

et al.

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(4), P. 776 - 780

Published: Feb. 20, 2023

Language: Английский

Correlates of protection against SARSCoV‐2 infection and COVID‐19 disease DOI
David Goldblatt, Galit Alter, Shane Crotty

et al.

Immunological Reviews, Journal Year: 2022, Volume and Issue: 310(1), P. 6 - 26

Published: June 5, 2022

Antibodies against epitopes in S1 give the most accurate CoP infection by SARS-CoV-2 coronavirus. Measurement of those antibodies neutralization or binding assays both have predictive value, with antibody titers giving highest statistical correlation. However, protective functions are multiple. multiple other than influence efficacy. The role cellular responses can be discerned respect to CD4

Language: Английский

Citations

241

Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines DOI Creative Commons
Alessandro Sette, Shane Crotty

Immunological Reviews, Journal Year: 2022, Volume and Issue: 310(1), P. 27 - 46

Published: June 22, 2022

Immunological memory is the basis of protective immunity provided by vaccines and previous infections. can develop from multiple branches adaptive immune system, including CD4 T cells, CD8 B long-lasting antibody responses. Extraordinary progress has been made in understanding to SARS-CoV-2 infection COVID-19 vaccines, addressing development; quantitative qualitative features different cellular anatomical compartments; durability each component antibodies. Given sophistication measurements; size human studies; use longitudinal samples cross-sectional head-to-head comparisons between or for 1 year already supersedes that any other acute infectious disease. This knowledge may help inform public policies regarding as well scientific development future against diseases.

Language: Английский

Citations

216

Imprinted antibody responses against SARS-CoV-2 Omicron sublineages DOI Creative Commons
Young‐Jun Park, Dora Pinto, Alexandra C. Walls

et al.

Science, Journal Year: 2022, Volume and Issue: 378(6620), P. 619 - 627

Published: Oct. 20, 2022

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry distinct spike mutations resulting in escape from antibodies induced by previous infection or vaccination. We show that hybrid immunity vaccine boosters elicit plasma-neutralizing against BA.1, BA.2, BA.2.12.1, and BA.4/5, breakthrough infections, but not vaccination alone, induce neutralizing the nasal mucosa. Consistent with immunological imprinting, most derived memory B cells plasma of cases cross-react Wuhan-Hu-1, BA.4/5 receptor-binding domains, whereas primary infections narrow specificity up to 6 months after infection. Although clinical have reduced neutralization Omicron, we identified an ultrapotent pan-variant–neutralizing antibody is a strong candidate for development.

Language: Английский

Citations

199

Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes DOI Creative Commons

Jasmin Quandt,

Alexander Muik,

Nadine Salisch

et al.

Science Immunology, Journal Year: 2022, Volume and Issue: 7(75)

Published: June 2, 2022

Omicron is the evolutionarily most distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) to date. We report that BA.1 breakthrough infection in BNT162b2-vaccinated individuals resulted strong neutralizing activity against BA.1, BA.2, and previous SARS-CoV-2 VOCs but not sublineages BA.4 BA.5. induced a robust recall response, primarily expanding memory B (B

Language: Английский

Citations

192

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines DOI Creative Commons
John E. Bowen, Amin Addetia, Ha V. Dang

et al.

Science, Journal Year: 2022, Volume and Issue: 377(6608), P. 890 - 894

Published: July 19, 2022

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the previously dominant BA.1 BA.4 BA.5 increasing in prevalence worldwide. We show that large number sublineage spike mutations leads to enhanced angiotensin-converting enzyme (ACE2) binding, reduced fusogenicity, dampening plasma neutralizing activity elicited by infection or seven clinical vaccines relative ancestral virus. Administration a homologous heterologous booster based on Wuhan-Hu-1 sequence markedly increased antibody titers breadth against BA.1, BA.2, BA.2.12.1, BA.4, across all evaluated. Our data suggest although sublineages evade polyclonal responses primary vaccine series, boosters may provide sufficient protection Omicron-induced disease.

Language: Английский

Citations

175

Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies DOI Creative Commons
Delphine Planas, Timothée Bruel, Isabelle Staropoli

et al.

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: Feb. 14, 2023

Abstract Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 lineages has led to the emergence several new subvariants, including BA.2.75.2, BA.4.6. BQ.1.1. The subvariant BQ.1.1 became predominant in many countries December 2022. subvariants carry an additional often redundant set mutations spike, likely responsible for increased transmissibility immune evasion. Here, we established a viral amplification procedure easily isolate strains. We examined their sensitivity 6 therapeutic monoclonal antibodies (mAbs) 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 breakthrough infection. Ronapreve (Casirivimab Imdevimab) Evusheld (Cilgavimab Tixagevimab) lose antiviral efficacy against BA.2.75.2 BQ.1.1, whereas Xevudy (Sotrovimab) remaine weakly active. is also resistant Bebtelovimab. Neutralizing titers triply vaccinated individuals are low undetectable 4 months after boosting. A infection increases these titers, which remains about 18-fold lower than BA.1. Reciprocally, more efficiently neutralization BA.2.75.2. Thus, trajectory novel facilitates spread immunized populations raises concerns most available mAbs.

Language: Английский

Citations

169

Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants DOI Creative Commons
Venice Servellita, Abdullah M. Syed, Mary Kate Morris

et al.

Cell, Journal Year: 2022, Volume and Issue: 185(9), P. 1539 - 1548.e5

Published: March 18, 2022

Language: Английский

Citations

162

ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies DOI Creative Commons
Jun Siong Low, Josipa Jerak, M. Alejandra Tortorici

et al.

Science, Journal Year: 2022, Volume and Issue: 377(6607), P. 735 - 742

Published: July 12, 2022

The coronavirus spike glycoprotein attaches to host receptors and mediates viral fusion. Using a broad screening approach, we isolated seven monoclonal antibodies (mAbs) that bind all human-infecting proteins from severe acute respiratory syndrome 2 (SARS-CoV-2) immune donors. These mAbs recognize the fusion peptide acquire affinity breadth through somatic mutations. Despite targeting conserved motif, only some show neutralizing activity in vitro against alpha- betacoronaviruses, including animal coronaviruses WIV-1 PDF-2180. Two selected also neutralize Omicron BA.1 BA.2 authentic viruses reduce burden pathology vivo. Structural functional analyses showed peptide–specific bound with different modalities cryptic epitope hidden prefusion stabilized spike, which became exposed upon binding of angiotensin-converting enzyme (ACE2) or ACE2-mimicking mAbs.

Language: Английский

Citations

146

T Cell Responses to SARS-CoV-2 DOI
Alessandro Sette, John Sidney, Shane Crotty

et al.

Annual Review of Immunology, Journal Year: 2023, Volume and Issue: 41(1), P. 343 - 373

Published: Feb. 8, 2023

A large body of evidence generated in the last two and a half years addresses roles T cells SARS-CoV-2 infection following vaccination. Infection or vaccination induces multi-epitope CD4 CD8 cell responses with polyfunctionality. Early have been associated mild COVID-19 outcomes. In concert animal model data, these results suggest that while antibody are key to prevent infection, may also play valuable reducing disease severity controlling infection. memory after is sustained for at least six months. While neutralizing impacted by variants, most preserved. This review highlights extensive progress made, data knowledge gaps remain, our understanding vaccines.

Language: Английский

Citations

122

Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection DOI Creative Commons
Chengzi I. Kaku,

Alan Bergeron,

Clas Ahlm

et al.

Science Immunology, Journal Year: 2022, Volume and Issue: 7(73)

Published: May 12, 2022

Understanding immune responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection will facilitate the development of next-generation vaccines. Here, we profiled spike (S)–specific B cell Omicron/BA.1 in messenger RNA–vaccinated donors. The antibody response was characterized by high levels somatic hypermutation and a bias toward recognition ancestral SARS-CoV-2 strains, suggesting early activation vaccine-induced memory cells. BA.1 induced shift immunodominance hierarchy from S2 subunit, which is highly conserved across variants concern (VOCs), antigenically variable receptor binding domain (RBD). A large proportion RBD-directed neutralizing antibodies isolated donors displayed convergent sequence features broadly recognized VOCs. Together, these findings provide insights into role preexisting immunity shaping to heterologous variant exposure.

Language: Английский

Citations

120